Amy Mao

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.

Cooley advised the underwriters in Erasca’s $100 million follow-on offering of 15,384,616 shares of common stock at a public offering price of $6.50 per share. Erasca is a clinical-stage biopharmaceutical company discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Kristin VanderPas and Denny Won led the Cooley team.

Cooley advised the underwriters on Ascendis Pharma’s $460 million follow-on offering. J.P. Morgan Securities, Morgan Stanley, Evercore Group, and SVB Leerink acted as joint book-running managers for the offering. Ascendis is a biopharmaceutical company applying its TransCon technologies to create new and potentially best-in-class therapies. Partners Jonie Kondracki, Charlie Kim, and Div Gupta led the Cooley team representing the underwriters.

Cooley advised the underwriters on Erasca’s $345 million initial public offering of 21,562,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering. Erasca, whose securities now trade on the Nasdaq Global Select Market under the symbol ERAS, is a clinical-stage precision oncology company focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.

Cooley advised the underwriters on Singular Genomics Systems’ $258.1 million initial public offering of 11,730,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. UBS Securities acted as a book-running manager for the offering, and J.P. Morgan Securities, Goldman Sachs, BofA Securities, and Cowen and Company acted as joint book-running managers. Singular Genomics Systems, whose securities now trade on the Nasdaq Global Select Market  under the symbol OMIC, is a life sciences technology company. Partners Charlie Kim, Sean Clayton and Kristin VanderPas led the Cooley team.